#GIM2 - Twitter Hashtag

over 3 years ago

1/3 Just published in @TheLancetOncol the 15-y follow-up data of #GIM2 trial: ✅ Impressive benefit both in #DFS (+8.5%) and #OS (+7%) rates of dose-dense adjuvant CT in high risk breast cancer patients.

Lucarecco's tweet photo. 1/3
Just published in @TheLancetOncol the 15-y follow-up data of #GIM2 trial:

✅ Impressive benefit both in #DFS (+8.5%) and #OS (+7%) rates of dose-dense adjuvant CT in high risk breast cancer patients. https://t.co/weUC0QVrSx

1

18

5

1

0

Matteo Lambertini, MD PhD @matteolambe

over 3 years ago · Genoa

Finally out in @TheLancetOncol 15-y follow up data of #GIM2 trial: no need to add #fluorouracil to anthracycline-based #chemotherapy and impressive benefit of dose-dense adjuvant CT in high risk patients including those with HR+ #BreastCancer @OncoAlert https://t.co/cNcveWDvDi

2

46

11

2

0

Paolo Tarantino

@PTarantinoMD

over 3 years ago

15y results of #GIM2 are now published on @TheLancetOncol, confirming no benefit from adding 5FU & sign benefit of dose dense adj chemo schedule. Read Stefania Morganti’s & @stolaney1’s comment to put the results into the context of modern adj regimens. https://t.co/Xb6ClCHbpd

PTarantinoMD's tweet photo. 15y results of #GIM2 are now published on @TheLancetOncol, confirming no benefit from adding 5FU & sign benefit of dose dense adj chemo schedule. Read Stefania Morganti’s & @stolaney1’s comment to put the results into the context of modern adj regimens.
https://t.co/Xb6ClCHbpd https://t.co/qV4Is2a1Ef

0

48

14

8

0

Matteo Lambertini, MD PhD @matteolambe

almost 4 years ago

Updated data from #GIM2 trial presented at @AIOMtweet #AIOM22 by prof @delmastro_lucia confirming no benefit of adding 5-FU and the crucial role of dose-dense adjuvant CT in high risk #BreastCancer patients including those with ER+ #bcsm @UniGenova @SanMartino_Ge #UNIGEnonsiferma

matteolambe's tweet photo. Updated data from #GIM2 trial presented at @AIOMtweet #AIOM22 by prof @delmastro_lucia confirming no benefit of adding 5-FU and the crucial role of dose-dense adjuvant CT in high risk #BreastCancer patients including those with ER+ #bcsm
@UniGenova @SanMartino_Ge #UNIGEnonsiferma https://t.co/SvocmG3Y22

1

31

12

1

0

Gustavo Werutsky @GustavoWerutsky

almost 4 years ago

#GIM2 trial confirms the benefit of dose-dense chemotherapy for high risk early stage BC, specially in TNBC. More strikingly, after 15 years about 40% of patients will relapse! long-term FU is critical in BC clinical trials; congrats for the Italian group #ESMO2022 @myESMO

GustavoWerutsky's tweet photo. #GIM2 trial confirms the benefit of dose-dense chemotherapy for high risk early stage BC, specially in TNBC. More strikingly, after 15 years about 40% of patients will relapse! long-term FU is critical in BC clinical trials; congrats for the Italian group #ESMO2022 @myESMO https://t.co/h2mWLexxa6

0

4

1

0

Fabio Puglisi @puglisi_fabio

about 5 years ago

Proud to share our recent publication on @Nature_NPJ Data from #GIM2 trial show that magnitude of #Dosedense chemotherapy benefit in pts with N+ HR-pos HER2-neg #EBC varies according to #CPRS #STEPP #prognosis #absolutebenefit 👉https://t.co/KvwxE0FdLs

puglisi_fabio's tweet photo. Proud to share our recent publication on @Nature_NPJ
Data from #GIM2 trial show that magnitude of #Dosedense chemotherapy benefit in pts with N+ HR-pos HER2-neg #EBC varies according to #CPRS
#STEPP #prognosis #absolutebenefit

👉https://t.co/KvwxE0FdLs https://t.co/ma5u5Y0aXb

1

24

6

0

Matteo Lambertini, MD PhD @matteolambe

about 7 years ago

@NicoleKuderer @aftimosp @weoncologists @bozovicspa @FAndreMD @StoverLab @Nikhilwagle @DrSGraff @tmprowell @CarmenCalfa @DrHBurstein @tsemiglazovaMD Thanks @NicoleKuderer for the question: we stopped using 5FU after the publication of the Italian #GIM2 trial @delmastro_lucia et al...definitively ddAC and not FEC!

matteolambe's tweet photo. @NicoleKuderer @aftimosp @weoncologists @bozovicspa @FAndreMD @StoverLab @Nikhilwagle @DrSGraff @tmprowell @CarmenCalfa @DrHBurstein @tsemiglazovaMD Thanks @NicoleKuderer for the question: we stopped using 5FU after the publication of the Italian #GIM2 trial @delmastro_lucia et al...definitively ddAC and not FEC! https://t.co/yJ0RtrYbYi

3

14

5

2

0

Arlindo R Ferreira @ajrsferreira

over 7 years ago

Intriguing results in HER2+ tumors and ddCT by @matteolambe using #GIM2 trial data

Matteo Lambertini, MD PhD @matteolambe

over 7 years ago

Our data from the #GIM2 trial (PI @delmastro_lucia from @UniGenova @SanMartino_Ge) showing that #DoseDense chemotherapy improves outcomes in high risk #BreastCancer patients but may not be needed in those with #HER2+ tumors receiving #Trastuzumab #ESMOBreast19 #OncoAlert #bcsm

matteolambe's tweet photo. Our data from the #GIM2 trial (PI @delmastro_lucia from @UniGenova @SanMartino_Ge) showing that #DoseDense chemotherapy improves outcomes in high risk #BreastCancer patients but may not be needed in those with #HER2+ tumors receiving #Trastuzumab
#ESMOBreast19 #OncoAlert #bcsm https://t.co/O2rRKLztBa

0

16

5

0

1

3

0

Matteo Lambertini, MD PhD @matteolambe

over 7 years ago

Our data from the #GIM2 trial (PI @delmastro_lucia from @UniGenova @SanMartino_Ge) showing that #DoseDense chemotherapy improves outcomes in high risk #BreastCancer patients but may not be needed in those with #HER2+ tumors receiving #Trastuzumab #ESMOBreast19 #OncoAlert #bcsm

0

16

5

0

Matteo Lambertini, MD PhD @matteolambe

over 7 years ago

Day 3 at #ESMOBreast19: excited to present our exploratory analysis of the #GIM2 trial investigating the benefit of #DoseDense #chemotherapy in the subgroup of patients with #HER2-positive #BreastCancer before and after the introduction of #trastuzumab #OncoAlert #bcsm @OncoAlert

matteolambe's tweet photo. Day 3 at #ESMOBreast19: excited to present our exploratory analysis of the #GIM2 trial investigating the benefit of #DoseDense #chemotherapy in the subgroup of patients with #HER2-positive #BreastCancer before and after the introduction of #trastuzumab
#OncoAlert #bcsm @OncoAlert https://t.co/X8nq0VHFoz

1

24

6

0

Beatriz Martinez @BeaEMartinez

over 7 years ago · Mendoza

👉🏼En @ciudaddemendoza hemos trabajado en la generación de fuentes no convencionales de energía 👉🏼Vamos a transformar el 100% de nuestro alumbrado a Tecnología LED, 👉🏼Hemos instalado paneles solares en el #Gim2 y lo haremos también en la #NaveCultural @rodysuarez @UlpianoSuarez

Buddha 💸 @BuddhaTrials

over 7 years ago · Mendoza

En la @ciudaddemendoza acompañamos esta política a través del impulso de energías alternativas. #CambiandoMendoza #Asamblea2019 #HaciendoQueElEstadoFuncione

0

16

2

0

7

1

0

Abinesh Arjunan

@The_Abinesh

over 8 years ago

உலக முதலீட்டாளர்கள் மாநாடு தொடர்பாக சென்னை தலைமைச் செயலகத்தில் முதல்வர் பழனிசாமி தலைமையில் ஆய்வுக்கூட்டம் நடைபெறவுள்ளது #TNGovt #GIM2

2

5

3

0

Manuraj S

@manuraj1983

over 8 years ago

Slow claps to @CMOTamilNadu who wants to hold #GIM2 when the investment has dwindled to less than 1% after the first Global Investment Meet. #ADMKFails https://t.co/yxlfNXQhL9

Dr P Thiaga Rajan (PTR)

@ptrmadurai

over 8 years ago

Shocking! More evidence that the TN Govt. is non-functional & TN Ministers who claim otherwise have lost touch with reality. Those who are extra-constitutionally keeping this Govt. alive for political reasons must share blame for the lack of growth & jobs https://t.co/x8e1XSsLg3

15

248

154

0

1

27

8

0